MiMedx Group Inc (MDXG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $468.42M
Last updated: Nov 17, 2026 at 11:05 AM ET
MiMedx Group Inc (MDXG) Earnings: Report Dates and Results
MiMedx Group (MDXG) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, MiMedx Group reported EPS of -$0.01. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MDXG has an expected report date of Feb 23, 2027.
MDXG Earnings Call
The latest MDXG earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, MDXG beat 17, missed 13 and matched 7. Revenue for the quarter ended Sep 30, 2026 was $62.28M, down 45.2% from $113.72M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.01 | N/A | N/A | N/A | N/A | -106.7% | N/A | 0 up, 2 down | Oct 28, 2026 | $62.28M |
| Jun 30, 2026 | -$0.05 | -$0.03 | -$0.04 - -$0.03 | -66.67% | Miss | -150.0% | 3 | 0 up, 2 down | Jul 29, 2026 | $64.36M |
| Mar 31, 2026 | -$0.05 | -$0.04 | -$0.08 - $0.00 | -25.00% | Miss | -200.0% | 4 | 0 up, 2 down | Apr 29, 2026 | $58.99M |
| Dec 31, 2025 | $0.14 | $0.09 | $0.09 - $0.13 | +50.70% | Beat | +100.0% | 4 | 1 up, 0 down | Feb 25, 2026 | $118.09M |
| Sep 30, 2025 | $0.15 | $0.08 | $0.07 - $0.08 | +87.50% | Beat | +114.3% | 2 | 0 up, 0 down | Oct 29, 2025 | $113.72M |
| Jun 30, 2025 | $0.10 | $0.06 | $0.05 - $0.06 | +66.67% | Beat | +25.0% | 2 | 0 up, 2 down | Jul 30, 2025 | $98.61M |
| Mar 31, 2025 | $0.05 | $0.06 | $0.05 - $0.06 | -16.67% | Miss | -28.6% | 2 | 1 up, 0 down | Apr 30, 2025 | $88.20M |
| Dec 31, 2024 | $0.07 | $0.08 | $0.07 - $0.08 | -6.67% | Miss | -78.1% | 2 | 2 up, 0 down | Feb 26, 2025 | $92.91M |
| Sep 30, 2024 | $0.07 | $0.05 | $0.04 - $0.05 | +40.00% | Beat | +40.0% | 5 | 0 up, 0 down | Oct 30, 2024 | $84.06M |
| Jun 30, 2024 | $0.08 | $0.08 | $0.05 - $0.10 | 0.00% | In line | N/A | 7 | 1 up, 0 down | Jul 31, 2024 | $87.21M |
| Mar 31, 2024 | $0.07 | $0.04 | $0.03 - $0.06 | +75.00% | Beat | N/A | 6 | 0 up, 0 down | Apr 30, 2024 | $84.71M |
| Dec 31, 2023 | $0.32 | $0.07 | $0.06 - $0.08 | +357.14% | Beat | N/A | 4 | 0 up, 0 down | Feb 28, 2024 | $86.83M |
| Sep 30, 2023 | $0.05 | $0.05 | $0.04 - $0.05 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Oct 30, 2023 | $81.71M |
| Jun 30, 2023 | $0.00 | -$0.03 | -$0.05 - $0.01 | +84.67% | Beat | N/A | 4 | 1 up, 0 down | Aug 1, 2023 | $81.26M |
| Mar 31, 2023 | -$0.03 | -$0.07 | -$0.10 - -$0.07 | +57.14% | Beat | N/A | 3 | 0 up, 0 down | May 2, 2023 | $71.68M |
| Dec 31, 2022 | -$0.02 | -$0.04 | -$0.09 - $0.00 | +50.00% | Beat | -300.0% | 3 | 0 up, 0 down | Feb 28, 2023 | $74.38M |
| Sep 30, 2022 | -$0.06 | -$0.12 | -$0.12 - -$0.03 | +50.00% | Beat | N/A | 4 | 0 up, 0 down | Nov 2, 2022 | $67.69M |
| Jun 30, 2022 | -$0.08 | -$0.08 | -$0.08 - -$0.02 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Aug 2, 2022 | $66.88M |
| Mar 31, 2022 | -$0.09 | -$0.10 | -$0.10 - -$0.10 | +10.00% | Beat | N/A | 2 | 0 up, 0 down | May 3, 2022 | $58.89M |
| Dec 31, 2021 | $0.01 | -$0.03 | -$0.08 - $0.01 | +133.33% | Beat | N/A | 3 | 0 up, 0 down | Feb 28, 2022 | $50.81M |
| Sep 30, 2021 | -$0.01 | -$0.07 | -$0.12 - -$0.05 | +85.71% | Beat | -103.7% | 3 | N/A | Nov 2, 2021 | $63.07M |
| Jun 30, 2021 | -$0.05 | -$0.08 | -$0.12 - -$0.02 | +37.50% | Beat | -171.4% | 3 | N/A | Aug 3, 2021 | $68.17M |
| Mar 31, 2021 | -$0.09 | -$0.19 | -$0.19 - -$0.19 | +52.63% | Beat | N/A | 1 | N/A | Apr 28, 2021 | $59.97M |
| Dec 31, 2020 | -$0.17 | -$0.05 | -$0.05 - -$0.05 | -240.00% | Miss | -144.7% | 1 | N/A | Mar 8, 2021 | $68.55M |
| Sep 30, 2020 | $0.27 | N/A | N/A | N/A | N/A | +145.5% | N/A | N/A | Nov 4, 2020 | $64.30M |
| Jun 30, 2020 | $0.07 | $0.12 | N/A | -41.67% | Miss | N/A | N/A | N/A | Jul 6, 2020 | $53.65M |
| Mar 31, 2020 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2020 | $61.74M |
| Dec 31, 2019 | $0.38 | $0.09 | N/A | +322.22% | Beat | N/A | N/A | N/A | Mar 17, 2020 | $76.40M |
| Sep 30, 2019 | $0.11 | $0.15 | N/A | -26.67% | Miss | N/A | N/A | N/A | Oct 31, 2019 | $88.86M |
| Jun 30, 2019 | -$0.16 | $0.14 | N/A | -214.29% | Miss | -1087.7% | N/A | N/A | Jul 31, 2019 | $67.44M |
| Mar 31, 2019 | -$0.12 | $0.13 | N/A | -192.31% | Miss | -233.3% | N/A | N/A | Apr 26, 2019 | $66.56M |
| Dec 31, 2018 | -$0.12 | $0.14 | N/A | -189.07% | Miss | -224.7% | N/A | N/A | Feb 21, 2019 | $92.59M |
| Sep 30, 2018 | -$0.33 | $0.13 | N/A | -355.23% | Miss | -514.8% | N/A | N/A | Oct 25, 2018 | $86.96M |
| Jun 30, 2018 | $0.02 | $0.11 | N/A | -85.27% | Miss | -76.9% | N/A | N/A | Jul 26, 2018 | $95.42M |
| Mar 31, 2018 | $0.09 | $0.09 | N/A | 0.00% | In line | +28.6% | N/A | N/A | Apr 26, 2018 | $84.15M |
| Dec 31, 2017 | $0.10 | $0.07 | N/A | +42.86% | Beat | +42.9% | 1 | N/A | Mar 31, 2018 | $87.55M |
| Sep 30, 2017 | $0.08 | $0.08 | $0.06 - $0.11 | 0.00% | In line | +33.3% | 6 | N/A | Oct 26, 2017 | $84.57M |
| Jun 30, 2017 | $0.07 | $0.07 | $0.06 - $0.08 | 0.00% | In line | +40.0% | 6 | N/A | Jul 26, 2017 | $76.41M |
| Mar 31, 2017 | $0.07 | $0.07 | N/A | 0.00% | In line | +75.0% | N/A | N/A | Apr 28, 2017 | $72.61M |
| Dec 31, 2016 | $0.07 | $0.08 | N/A | -12.50% | Miss | -41.7% | N/A | N/A | Feb 23, 2017 | $46.57M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.44, up 51.7% from the year before. It was $0.22 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.44 | +51.7% |
| Dec 31, 2024 | $0.29 | -13.5% |
| Dec 31, 2023 | $0.34 | N/A |
| Dec 31, 2022 | -$0.25 | N/A |
| Dec 31, 2021 | -$0.14 | -255.6% |
| Dec 31, 2020 | $0.09 | -57.1% |
| Dec 31, 2019 | $0.21 | N/A |
| Dec 31, 2018 | -$0.35 | -209.5% |
| Dec 31, 2017 | $0.32 | +45.5% |
| Dec 31, 2016 | $0.22 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,000 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,030 | 7 | |
| 2026Q2 | Jun 30, 2026 | 6,453 | 8 | |
| 2025Q4 | Dec 31, 2025 | 5,753 | 8 | |
| 2025Q3 | Sep 30, 2025 | 5,979 | 9 | |
| 2025Q2 | Jun 30, 2025 | 5,332 | 8 | |
| 2025Q1 | Mar 31, 2025 | 5,624 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,902 | 9 | |
| 2024Q3 | Sep 30, 2024 | 6,660 | 9 |
2026Q3 Earnings Call
Opening remarks
Matthew Notarianni Head of Investor Relations Thank you, operator, and good afternoon, everyone. We are pleased to welcome you to MiMedx's third quarter 2026 operating and financial results conference call. With me on today's call are Chief Executive Officer, Joe Capper; and Chief Financial Officer, Doug Rice. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at mimedx.com. Joe will kick us off today with a summary of our third quarter 2026 operating and financial highlights, and Doug will provide a detailed review of our results for the quarter. And then we will conclude with some additional updates before we open the line for your questions. Before we begin, I would like to remind you that our comments today will include forward-looking statements, including statements regarding future sales, operating results and cash balance growth, future margins and expenses, our product portfolios, expected market sizes for our products and expectations regarding the Sanara acquisition, including expected benefits and financial performance of the combined company. These expectations are subject to risks and uncertainties, and actual results may differ materially from those anticipated due to many factors, including competition, access to customers, the reimbursement environment and unforeseen circumstances and delays. Additional factors that could impact outcomes and our results include those described in the Risk Factors section of our annual report on Form 10-K and our quarterly report on Form 10-Q. Also, our comments today include non-GAAP financial measures, and we provide a reconciliation to the most comparable GAAP measures in our press release, which is available on our website at mimedx.com. Furthermore, all our statements are as of today, October 28, 2026, and we have no obligation to update any forward-looking statement we make. With that, I'm now pleased to turn the call over to Joe Capper. Joe?
Joseph Capper CEO Thanks, Matt, and good afternoon, everyone. Thank you for joining us on today's call. The results and trends of the third quarter reinforce the strategic rationale for the direction we are taking the company. Our Surgical business performed well despite somewhat softer procedure volumes, a trend that has been reported across the industry, while our Wound Care business continues to work through the reset precipitated by the changes to Medicare reimbursement. Additionally, we made significant progress preparing for the acquisition and subsequent integration of Sanara MedTech. However, as previously announced, the FTC has issued a second request for information, which extends the Hart-Scott-Rodino waiting period. We will work diligently with the commission to satisfy its inquiry, and we remain fully committed to the acquisition. We believe the combination of the two companies will enhance our ability to serve the marketplace and benefit patients.
Frequently Asked Questions About MDXG
When is MiMedx Group's next earnings date?
MiMedx Group's next earnings report is expected for Feb 23, 2027.
What EPS do analysts expect from MDXG next quarter?
The consensus EPS estimate for MiMedx Group for the quarter ending Dec 31, 2026 is -$0.03 from 7 analysts, with estimates from -$0.03 to -$0.03.
How often does MDXG beat earnings estimates?
MiMedx Group beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +16.23%.
MDXG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors